ZYME
Zymeworks BC Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
zymeworks is a privately held biotherapeutics company that is developing best-in-class azymetric™ bi specific antibodies and antibody drug conjugates for the treatment of oncology, autoimmunity and inflammatory diseases. the company’s novel azymetric™ and albucore™ platforms, and its proprietary zymecad™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics targeted across a range of indications. zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations. more information on zymeworks can be found at www.zymeworks.com.
Market Cap: 856 Million
Primary Exchange: NASDAQ
Website: https://www.zymeworks.com/
Shares Outstanding: 70 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.170940225299762
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 441 trading days
From: 2018-06-01 To: 2019-06-07
Lowest Point:
Zymeworks to Present at Raymond James Life Sciences and MedTech Conference
via: Business Wire at 2019-06-12 13:00:00:000
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Raymond James Life Sciences and MedTech Conference taking place June 18-19, 2019 in New York, NY. The Compa… read more...
Zymeworks to Present at Raymond James Life Sciences and MedTech Conference
via: Business Wire at 2019-06-12 13:00:00:000
Zymeworks Inc. (NYSE/TSX: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced that management will present at the upcoming Raymond James Life Sciences and MedTech Conference taking place June 18-19, 2019 in New York, NY. The Compa… read more...
Zymeworks: Leader In Bispecifics Space Makes Substantial Headway
via: SeekingAlpha at 2019-06-11 02:07:59:000
Shares of Zymeworks ( ZYME ) have nearly doubled since I suggested that readers "buy the dip" in February 2018. In that article, I pointed out that a bet on the stock was not merely a wager on prospects for lead program ZW25, but also on its impressive platform technologies with several part… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|